SynthesisBrain and behavior2019
CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis.
Synthesis in Brain and behavior, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 6 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Magnetoencephalography studies in migraine and headache disorders: A systematic review.Headache · 2025Pooled it
- Assessing the effectiveness of greater occipital nerve block in chronic migraine: a systematic review and meta-analysis.BMC neurology · 2024Pooled it
- Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.European journal of medical research · 2022Pooled it
- Optimal treatment strategy of fremanezumab in migraine prevention: a systematic review with network meta-analysis of randomized clinical trials.Scientific reports · 2020Pooled it
- Effects of Anti-Calcitonin Gene-Related Peptide for Migraines: A Systematic Review with Meta-Analysis of Randomized Clinical Trials.International journal of molecular sciences · 2019Pooled it
- CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis.Brain and behavior · 2019Pooled it
- Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of aCephalalgia : an international journal of headache · 2021Trial
- Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine.Headache · 2020Trial
- The Effect of Fremanezumab on Pain in Patients with Complex Regional Pain Syndrome: Study Protocol of a Randomized, Double-Blind, Proof-of-Concept, Placebo-Controlled Trial.Brain sciences · 2025Article
- Effects of Anti-CGRP Monoclonal Antibodies on Neurophysiological and Clinical Outcomes: A Combined Transcranial Magnetic Stimulation and Algometer Study.Neurology international · 2024Article
- Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients.Biomedicines · 2024Article
- A Digital Health Application Allowing a Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Proof-of-Concept Data from a Retrospective Cohort Study.Journal of clinical medicine · 2022Article
- Class A and C GPCR Dimers in Neurodegenerative Diseases.Current neuropharmacology · 2022Review
- CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs.The journal of headache and pain · 2021Article
- Article
- Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Article
- Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis.Frontiers in pharmacology · 2021Article
- Temporomandibular disorders: a review of current concepts in aetiology, diagnosis and management.Oral surgery · 2020Article
- Gepants for abortive treatment of migraine: A network meta-analysis.Brain and behavior · 2020Article
- Can Monoclonal Antibodies against CGRP Offer New Treatment Options for Type 2 Diabetes?Journal of diabetes and clinical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta-analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic migraine.
methodsDatabase including Cochrane Library and PubMed were systematically searched for randomized controlled trials (RCTs) which are about CGRP mAb in preventing treatment of chronic migraine. Evaluating the bias and quality of RCTs was carried out according to the Cochrane collaboration's tool for assessing risk of bias. The data analysis was carried out by reviewer manager 5.2.
resultsTotally, 6 articles enrolled in the present meta-analysis, including 4 independent clinical trials and 3,166 patients. After pooled analysis, it indicated that CGRP mAb improved 50% responder rate (OR = 2.42, 95% CI = [2.04, 2.87], I
conclusionsCGRP mAb is an effective and safety preventive treatment for chronic migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.